Skip to Main Content

A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Conditions

Non-Hodgkin's Lymphoma

Phase III

What is the purpose of this trial?

The purpose of this trial is to assess the efficacy and safety of E7777 (improved purity ONTAK) in patients with persistent and recurrent cutaneous T-cell lymphoma. A lead-in dose-finding part will be used to determine the dose of E7777 that should be used to test efficacy and safety.

  • Trial with
    Eisai Pharmaceuticals
  • Start Date
    07/18/2017
  • End Date
    06/29/2019
Trial Image

For more information about this study, contact:

Laura Leary

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/27/2020
  • Study HIC
    #2000020362